Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis


Trial ID: NCT04396756


A Phase 2a, multicenter, 4-part, randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the safety, tolerability, and PK of once-daily treatment with PLN-74809 in participants with idiopathic pulmonary fibrosis.

Official Title

A Randomized, Double-blind, Dose-ranging, Placebo Controlled Phase 2a Evaluation of the Safety, Tolerability and Pharmacokinetics of PLN-74809 in Participants With Idiopathic Pulmonary Fibrosis (INTEGRIS-IPF)

Stanford Investigator(s)

Joshua Mooney
Joshua Mooney

Clinical Assistant Professor, Medicine - Pulmonary, Allergy & Critical Care Medicine


Inclusion Criteria:

   - Diagnosis of IPF based upon the Fleischner Society guidelines within 3 years from
   Screening (Part A) or based on ATS/ERS/JRS/ALAT 2018 guidelines within 5 years from
   Screening (Part B, C & D)

   - FVC % of predicted ≥45%

   - DLco (hemoglobin-adjusted) ≥30%

   - Participants receiving treatment for IPF with nintedanib or pirfenidone are allowed,
   if on a stable dose for at least 3 months

Exclusion Criteria:

   - Currently receiving or planning to initiate treatment for IPF (fibrosis) with agents
   not approved for that indication by the FDA

   - Forced expiratory volume during the first seconds of the forced breath (FEV1)/FVC
   ratio <0.7 at Screening

   - Clinical evidence of active infection, including but not limited to bronchitis,
   pneumonia, sinusitis that can affect FVC measurement or IPF progression

   - Known acute IPF exacerbation or suspicion by the Investigator of such, within 6 months
   of Screening

   - Smoking of any kind within 3 months of Screening


drug: PLN-74809

drug: Placebo


Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305